Chart Industries GTLS Biomedical — D&A
Discontinued — last reported Q4 '17
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Chart Industries in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The official record: Chart Industries’s 10-K, filed February 22, 2018, on SEC EDGAR. View the filing →
Questions, answered.
- What does biomedical — D&A mean?
- The non-cash cost of using up physical and intangible assets in the Biomedical segment.
- How do you interpret biomedical — D&A?
- High levels relative to revenue may indicate a capital-intensive segment or significant recent acquisition-related intangible amortization.
- How does biomedical — D&A compare across companies?
- Standard operating expense disclosure for manufacturing and technology segments.